Lilly partnered with Oxford-based Immunocore in an option-and-license agreement spanning multiple ImmTAC bispecific T-cell-receptor cancer candidates, with $45M up front and the rest in development and commercial milestones plus tiered royalties. One of four major-pharma ImmTAC pacts (also GSK, Genentech, AstraZeneca) signed by Immunocore in 2014.